NASDAQ:STROSutro Biopharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sutro Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.40 -0.79 (-7.75 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$9.38Now: $9.40▼$10.2850-Day Range$6.19MA: $9.73▼$11.5052-Week Range$6.00Now: $9.40▼$12.75Volume32,302 shsAverage Volume47,780 shsMarket Capitalization$217.14 millionP/E RatioN/ADividend YieldN/ABeta0.59 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.60, Sutro Biopharma has a potential upside of 97.9% from its current price of $9.40.Amount of Analyst CoverageSutro Biopharma has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesSutro Biopharma has received 75 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSutro Biopharma has received 84 “underperform” votes. (Add your “underperform” vote.)Community SentimentSutro Biopharma has received 52.83% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sutro Biopharma and other stocks. Vote “Outperform” if you believe STRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STRO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,903.00 in company stock.Percentage Held by InsidersOnly 28.90% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions49.70% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sutro Biopharma are expected to grow by 16.11% in the coming year, from ($2.98) to ($3.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.51 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STRO Previous Symbol CUSIPN/A CIKN/A Webhttp://www.sutrobio.com/ Phone650-392-8412Debt Debt-to-Equity RatioN/A Current Ratio3.90 Quick Ratio3.90Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$42.74 million Price / Sales5.08 Cash FlowN/A Price / Cash FlowN/A Book Value($8.47) per share Price / Book-1.11Profitability EPS (Most Recent Fiscal Year)($2.43) Net Income$-55,740,000.00 Net Margins-130.44% Return on EquityN/A Return on Assets-31.00%Miscellaneous Employees141 Outstanding Shares23,100,000Market Cap$217.14 million Next Earnings Date5/20/2020 (Estimated) OptionableNot Optionable Receive STRO News and Ratings via Email Sign-up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:STRO Rates by TradingView Sutro Biopharma (NASDAQ:STRO) Frequently Asked Questions How has Sutro Biopharma's stock been impacted by COVID-19 (Coronavirus)? Sutro Biopharma's stock was trading at $8.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STRO stock has increased by 15.9% and is now trading at $9.40. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Sutro Biopharma? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sutro Biopharma. When is Sutro Biopharma's next earnings date? Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Sutro Biopharma. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma Inc (NASDAQ:STRO) announced its earnings results on Monday, March, 16th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.69) by $0.05. The business had revenue of $11.31 million for the quarter, compared to analysts' expectations of $9.33 million. View Sutro Biopharma's earnings history. What price target have analysts set for STRO? 7 brokers have issued 12 month price objectives for Sutro Biopharma's shares. Their forecasts range from $16.00 to $22.00. On average, they anticipate Sutro Biopharma's stock price to reach $18.60 in the next year. This suggests a possible upside of 97.9% from the stock's current price. View analysts' price targets for Sutro Biopharma. What are Wall Street analysts saying about Sutro Biopharma stock? Here are some recent quotes from research analysts about Sutro Biopharma stock: 1. According to Zacks Investment Research, "Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California. " (3/19/2020) 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our 12-month, $18 price target on shares of Sutro is derived from a 13-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.60, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.3%, and tax rate of 15% beginning in FY 2029. Until clarity on Sutro’s collaboration with Celgene and Merck crystallizes, our $18 price target remains leveraged on the outcome of STRO-002’s safety and efficacy outcome, which represents approximately 67% of our rNPV of $12 per share." (5/7/2019) Has Sutro Biopharma been receiving favorable news coverage? News stories about STRO stock have been trending very negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sutro Biopharma earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutSutro Biopharma. Are investors shorting Sutro Biopharma? Sutro Biopharma saw a increase in short interest in March. As of March 13th, there was short interest totaling 68,900 shares, an increase of 53.8% from the February 27th total of 44,800 shares. Based on an average trading volume of 23,800 shares, the short-interest ratio is currently 2.9 days. Approximately 0.8% of the company's shares are sold short. View Sutro Biopharma's Current Options Chain. Who are some of Sutro Biopharma's key competitors? Some companies that are related to Sutro Biopharma include I-Mab (BDTX), NanoString Technologies (NSTG), Beam Therapeutics (BEAM), Sangamo Therapeutics (SGMO), Orchard Therapeutics (ORTX), Novavax (NVAX), Adverum Biotechnologies (ADVM), Krystal Biotech (KRYS), Passage Bio (PASG), Oyster Point Pharma (OYST), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), AVITA MED LTD/S (RCEL), GENFIT S A/ADR (GNFT) and Aerie Pharmaceuticals (AERI). What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Momo (MOMO), Vaxart (VXRT), AcelRx Pharmaceuticals (ACRX), Aduro BioTech (ADRO), Amarin (AMRN) and Fortress Biotech (FBIO). Who are Sutro Biopharma's key executives? Sutro Biopharma's management team includes the following people: Mr. William J. Newell, CEO & Director (Age 61)Dr. Trevor J. Hallam, Chief Scientific Officer (Age 60)Dr. Arturo M. Molina, Chief Medical Officer (Age 60)Dr. James R. Swartz Sc.D., Ph.D., Founder and Member of Scientific Advisory BoardMr. Edward C. Albini, CFO & Sec. (Age 61) When did Sutro Biopharma IPO? (STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Sutro Biopharma's stock symbol? Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO." How do I buy shares of Sutro Biopharma? Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Sutro Biopharma's stock price today? One share of STRO stock can currently be purchased for approximately $9.40. How big of a company is Sutro Biopharma? Sutro Biopharma has a market capitalization of $217.14 million and generates $42.74 million in revenue each year. The company earns $-55,740,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Sutro Biopharma employs 141 workers across the globe. View additional information about Sutro Biopharma. What is Sutro Biopharma's official website? The official website for Sutro Biopharma is http://www.sutrobio.com/. How can I contact Sutro Biopharma? Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412. This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: What is the Shanghai Stock Exchange Composite Index?
